Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
-
Andreas Pfützner
Abstract
Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP).
Methods: This cross-sectional study attempted to analyze the association of hsCRP levels with insulin resistance, β-cell dysfunction and macrovascular disease in 4270 non-insulin-treated patients with type 2 diabetes [2146 male, 2124 female; mean age ±SD, 63.9±11.1years; body mass index (BMI) 30.1±5.5kg/m2; disease duration 5.4±5.6years; hemoglobin A1c (HbA1c) 6.8±1.3%]. It consisted of a single morning visit with collection of a fasting blood sample. Observational parameters included several clinical scores and laboratory biomarkers.
Results: Stratification into cardiovascular risk groups according to hsCRP levels revealed that 934 patients had low risk (hsCRP <1mg/L), 1369 patients had intermediate risk (hsCRP 1–3mg/L), 1352 patients had high risk (hsCRP >3–10mg/L), and 610 patients had unspecific hsCRP elevation (>10mg/L). Increased hsCRP levels were associated with other indicators of diabetes-related cardiovascular risk (homeostatic model assessment, intact proinsulin, insulin, BMI, β-cell dysfunction, all p<0.001), but showed no correlation with disease duration or glucose control. The majority of the patients were treated with diet (34.1%; hsCRP levels 2.85±2.39mg/L) or metformin monotherapy (21.1%; 2.95±2.50mg/L hsCRP). The highest hsCRP levels were observed in patients treated with sulfonylurea (17.0%; 3.00±2.43mg/L).
Conclusions: Our results indicate that hsCRP may be used as a cardiovascular risk marker in patients with type 2 diabetes mellitus and should be evaluated in further prospective studies.
References
1. Howard B, Rodriguez B, Bennet P, Harris M, Hamman R, Kuller L, et al. Prevention Conference VI: diabetes and cardiovascular disease: writing group I: epidemiology. Circulation 2002; 105:e132–7.10.1161/01.CIR.0000013953.41667.09Search in Google Scholar
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229–34.10.1056/NEJM199807233390404Search in Google Scholar
3. Ross R. Artherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115–26.10.1056/NEJM199901143400207Search in Google Scholar
4. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999; 130:933–7.10.7326/0003-4819-130-11-199906010-00018Search in Google Scholar
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836–43.10.1056/NEJM200003233421202Search in Google Scholar
6. Willerson JT, Ridker PM. Inflammation as cardiovascular risk factor. Circulation 2004; 109(Suppl 1):II2–10.10.1161/01.CIR.0000129535.04194.38Search in Google Scholar
7. Ridker PM. High-sensitive C-reactive protein – potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103:1813–8.10.1161/01.CIR.103.13.1813Search in Google Scholar
8. Koenig W, Sund M, Froelich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237–42.10.1161/01.CIR.99.2.237Search in Google Scholar
9. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004; 109:1955–9.10.1161/01.CIR.0000125690.80303.A8Search in Google Scholar
10. Sellmayer A, Limmert T, Hoffmann U. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening? Int Angiol 2003; 22:15–23.Search in Google Scholar
11. Morrow D, Rifai N, Antman E, Weiner DL, McCabe CH, Cannon CP, et al. C-Reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31:1460–5.10.1016/S0735-1097(98)00136-3Search in Google Scholar
12. Maseri A. Inflammation, atherosclerosis and ischemic events: exploring the hidden side of the moon. N Engl J Med 1997; 336:1014–6.10.1056/NEJM199704033361409Search in Google Scholar
13. Forst T, Standl E, Hohberg C, Konrad T, Schulze J, Strotmann HJ, et al. IRIS-II Study: the IRIS-II score – assessment of a new clinical algorithm for the classification of insulin resistance in patients with type 2 diabetes. Diabet Med 2004; 21:1149–53.10.1111/j.1464-5491.2004.01298.xSearch in Google Scholar
14. Pfützner A, Kunt T, Mondok A, Pahler S, Konrad T, Luebben G, et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004; 27:682–7.10.2337/diacare.27.3.682Search in Google Scholar
15. Pfützner A, Standl E, Hohberg C, Konrad T, Strotmann HJ, Lübben G, et al. IRIS II Study: intact proinsulin is confirmed as highly specific marker for insulin resistance in a cross-sectional study design. Diabet Technol Ther 2005; 7:478–86.10.1089/dia.2005.7.478Search in Google Scholar
16. Pfützner A, Kunt T, Löbig M, Knesovic M, Forst T. Clinical and laboratory evaluation characteristics of two new chemiluminescence assays for intact and total proinsulin. Clin Chem Lab Med 2003; 41:1234–8.10.1515/CCLM.2003.189Search in Google Scholar
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–9.10.1007/BF00280883Search in Google Scholar
18. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabetic Med 2000; 17:299–307.10.1046/j.1464-5491.2000.00280.xSearch in Google Scholar
19. Pfützner A, Kann P, Pfützner AH, Kunt T, Larbig M, Weber MM, et al. Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes. Clin Lab 2004; 50:567–73.Search in Google Scholar
20. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167:73–9.10.1016/S0021-9150(02)00380-5Search in Google Scholar
21. Serrano Rios M. Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998; 28(Suppl 2):14–7.10.1046/j.1365-2362.1998.0280s2014.xSearch in Google Scholar PubMed
22. Haffner SM, Mykkänen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101:975–80.10.1161/01.CIR.101.9.975Search in Google Scholar
23. Yudkin JS. Increased proinsulin concentrations and excess risk of coronary heart disease in patients with diabetes and prediabetes. Circulation 2002; 106:e202.10.1161/01.CIR.0000041813.45120.C8Search in Google Scholar
24. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? Diabetes Care 1999; 22:696–9.10.2337/diacare.22.5.696Search in Google Scholar
25. Huupponen R. Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance. Med Toxicol 1987; 2:190–209.10.1007/BF03259864Search in Google Scholar
26. Paice BJ, Paterson KR, Lawson DH. Undesired effects of the sulphonylurea drugs. Adverse Drug React Acute Poisoning Rev 1985; 4:23–36.Search in Google Scholar
27. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Can Med Assoc J 2006; 174:169–74.10.1503/cmaj.050748Search in Google Scholar
28. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003; 29:207–22.10.1016/S1262-3636(07)70030-7Search in Google Scholar
29. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control – results from the Pioneer Study. J Am Coll Cardiol 2005; 45:1925–31.10.1016/j.jacc.2005.03.041Search in Google Scholar PubMed
30. Langenfeld M, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independent of glycemic control in patients with type 2 diabetes mellitus. Circulation 2005; 111:2525–31.10.1161/01.CIR.0000165072.01672.21Search in Google Scholar PubMed
31. Pfützner A, Hohberg C, Lübben G, Pahler S, Pfützner AH, Kann P, et al. Pioneer Study: PPARγ activation results in an overall improvement of clinical and metabolic markers associated with insulin resistance independent from long-term glucose control. Horm Metab Res 2005; 37:510–5.10.1055/s-2005-870320Search in Google Scholar PubMed
32. Pfützner A, Schöndorf T, Seidel D, Winkler K, Matthaei S, Hamann A, et al. Impact of rosiglitazone on β-cell function, insulin resistance and adiponektin concentrations – results from a double blind oral combination study with glimepiride. Metabolism 2006; 55:20–5.10.1016/j.metabol.2005.06.021Search in Google Scholar PubMed
33. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-Reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20–8.10.1056/NEJMoa042378Search in Google Scholar PubMed
34. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29–38.10.1056/NEJMoa042000Search in Google Scholar PubMed
35. Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of cardiovascular risk? Circulation 2004; 109:2818–25.10.1161/01.CIR.0000132467.45278.59Search in Google Scholar PubMed
©2006 by Walter de Gruyter Berlin New York
Articles in the same Issue
- CCLM: Expanding the science worldwide
- Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening
- Immunochemical quantification of free immunoglobulin light chains from an analytical perspective
- De novo deletion removes a conserved motif in the C-terminus of ABCA4 and results in cone-rod dystrophy
- Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients
- Influence of human haptoglobin polymorphism on oxidative stress induced by free hemoglobin on red blood cells
- Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia
- Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
- A longitudinal evaluation of urinary glycosaminoglycan excretion in normoalbuminuric type 1 diabetic patients
- National survey on the execution of the oral glucose tolerance test (OGTT) in a representative cohort of Italian laboratories
- The reduction of cholesteryl linoleate in lipoproteins: an index of clinical severity in β-thalassemia/Hb E
- Alterations in serum glycosaminoglycan profiles in Graves' patients
- Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients
- Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera
- Utilizing ultrafiltration to remove alkaline phosphatase from clinical analyzer water
- Measurement of serum monoclonal components: comparison between densitometry and capillary zone electrophoresis
- Salivary aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase: possible markers in periodontal diseases?
- Reticulocyte count, mean reticulocyte volume, immature reticulocyte fraction, and mean sphered cell volume in elite athletes: reference values and comparison with the general population
- Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece
- The effects of adrenocorticotrophic hormone and cortisol on homocysteine and vitamin B concentrations
- Plasma, salivary and urinary cotinine in non-smoker Italian women exposed and unexposed to environmental tobacco smoking (SEASD study)
- Cut-off values for total serum immunoglobulin E between non-atopic and atopic children in north-west Croatia
- Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures
- Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt
- Insufficient filling of vacuum tubes as a cause of microhemolysis and elevated serum lactate dehydrogenase levels. Use of a data-mining technique in evaluation of questionable laboratory test results
- Evaluation of three different specimen types (serum, plasma lithium heparin and serum gel separator) for analysis of certain analytes: clinical significance of differences in results and efficiency in use
- Comparative evaluation of a new immunoradiometric assay for corticotropin
- Mast cells in atherosclerosis as a source of the cytokine RANKL
- Falsely increased total serum protein due to dextran interference
Articles in the same Issue
- CCLM: Expanding the science worldwide
- Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening
- Immunochemical quantification of free immunoglobulin light chains from an analytical perspective
- De novo deletion removes a conserved motif in the C-terminus of ABCA4 and results in cone-rod dystrophy
- Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients
- Influence of human haptoglobin polymorphism on oxidative stress induced by free hemoglobin on red blood cells
- Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia
- Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
- A longitudinal evaluation of urinary glycosaminoglycan excretion in normoalbuminuric type 1 diabetic patients
- National survey on the execution of the oral glucose tolerance test (OGTT) in a representative cohort of Italian laboratories
- The reduction of cholesteryl linoleate in lipoproteins: an index of clinical severity in β-thalassemia/Hb E
- Alterations in serum glycosaminoglycan profiles in Graves' patients
- Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients
- Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera
- Utilizing ultrafiltration to remove alkaline phosphatase from clinical analyzer water
- Measurement of serum monoclonal components: comparison between densitometry and capillary zone electrophoresis
- Salivary aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase: possible markers in periodontal diseases?
- Reticulocyte count, mean reticulocyte volume, immature reticulocyte fraction, and mean sphered cell volume in elite athletes: reference values and comparison with the general population
- Serum homocysteine levels and paraoxonase 1 activity in preschool aged children in Greece
- The effects of adrenocorticotrophic hormone and cortisol on homocysteine and vitamin B concentrations
- Plasma, salivary and urinary cotinine in non-smoker Italian women exposed and unexposed to environmental tobacco smoking (SEASD study)
- Cut-off values for total serum immunoglobulin E between non-atopic and atopic children in north-west Croatia
- Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures
- Evaluation of serum levels of p53 in hepatocellular carcinoma in Egypt
- Insufficient filling of vacuum tubes as a cause of microhemolysis and elevated serum lactate dehydrogenase levels. Use of a data-mining technique in evaluation of questionable laboratory test results
- Evaluation of three different specimen types (serum, plasma lithium heparin and serum gel separator) for analysis of certain analytes: clinical significance of differences in results and efficiency in use
- Comparative evaluation of a new immunoradiometric assay for corticotropin
- Mast cells in atherosclerosis as a source of the cytokine RANKL
- Falsely increased total serum protein due to dextran interference
